customer service
Reader Domain Proteins

About Reaction Biology

Reaction Biology Corporation is an industry leader and innovator specializing in assay services and protein production for early-stage drug discovery. Founded in 2001, Reaction Biology offers a wide range of services, including robust biochemical, biophysical, electrophysiological and cell assay technologies for high throughput screening (HTS) and selectivity compound profiling. RBC's target covering is wide, covering more than 1000 different targets, heavily focused on kinase and epigenetic targets. We also offer relevant HTS assay reagents, including highly purified and characterized epigenetic proteins. On average, several million HTS and profiling reactions are performed per year. Over 750 companies worldwide, including pharmaceutical, biotech, academic, and nonprofit laboratories, utilize our biochemical and cellular assay services and purchase epigenetic proteins.

Matt Oristano- CEO/President
Mr. Oristano is President of Alda Inc, a private investment firm. In addition, he serves on the board of Spōk (Nasdaq: SPOK) and its audit committee. He is also on the board of Crystalplex Corporation. From 1993 to 1999, Mr. Oristano was Chairman and CEO of People's Choice TV Corp, a public wireless TV and internet company, which he founded in 1988 and sold to Sprint in 1999. Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.

Tom Petzinger, Jr.
Mr. Petzinger is CEO of LaunchCyte, a biotechnology development firm. Mr. Petzinger also serves as Chairman of Immunetrics Inc., Crystalplex Corp, Proteopure Inc., and Knopp Neurosciences. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. A Pulitzer nominee for numerous investigative stories, he has also written three best-selling business books. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.

Michael Kramer
Based in New York City, Mr. Kramer has had long experience advising firms and governments worldwide on financial transactions totaling hundreds of billions of dollars. He is currently the Founding Partner of Ducera Partners LLC. Previously, he has been a senior partner at Perella Weinberg Partners, a member of the Management Committee at Greenhill & Co, and head of M&A and Financial Restructuring for the firm of Houlihan Lokey Howard & Zukin.

Jonathan Kaufman, PhD
Dr. Kaufman is the CEO of Lipella Pharmaceuticals, Inc. Prior to co-founding Lipella, Dr.Kaufman was Vice President and Chief Science Officer of LaunchCyte LLC, a biotechnology corporate incubator. At LaunchCyte, Dr. Kaufman was co-founder of Proteopure Inc. and Knopp Neuroscience Inc.; served as the founding President of Crystalplex Corp.; served on the Boards of Reaction Biology Corp., Crystalplex Corp., and Immunetrics Inc.; and served as Secretary of Reaction Biology Corp. Prior to joining LaunchCyte, Dr. Kaufman served on the New Technology Committee in the Chemical Manufacturing Division of Merck& Co., and also served as a consultant to GlaxoSmithKline in the department of bioinformatics. Dr. Kaufman received his MBA in Finance from the Wharton School, and his PhD in Biophysics from the University of Pennsylvania School of Medicine.

Haiching Ma, PhD
Dr. Ma is the Chief Science Officer of RBC, where he developed and implemented the current RBC technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all RBC totaling over $12 million, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.


Matt Oristano

Haiching Ma, PhD

Robert Hartman

Kurumi Horiuchi, PhD
Director of Biochemistry

Yuren Wang, PhD
Director of Pharmacology & QC

Cindy Spadero
Director of Human Resources

Ekaterina Kuznetsova, PhD
Director of Product Development

Kelvin Lam, PhD
Director of Strategic Partnerships


Financial Conflict of Interest Policy

With the largest functional kinase activity assay panel in the industry, RBC provides kinase, epigenetic, and other profiling services to over 750 companies worldwide. RBC specializes in custom assay conditions, high quality reproducible data, and outstanding service.

Reaction Biology Corp. 1 Great Valley Parkway, Suite 2 Malvern, PA 19355 1-877-347-2368 or 610-722-0247
Reaction Biology Corp. © 2016 all rights reserved.